Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia.Circulation. 1974; 49: 476-488
Simon Broome Register Group. Risk of fatal coronary heart disease in familial hypercholesterolaemia. B Med J 1991;303:893–6.
- Additional risk factors influence excess mortality in heterozygous familial hypercholesterolaemia.Atherosclerosis. 2000; 149: 421-425
- Mortality over two centuries in large pedigree with familial hypercholesterolaemia: family tree mortality study.B.M.J. 2001; 322: 1019-1022
- Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia.N. Engl. J. Med. 1995; 333: 1301-1307
- Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels.JAMA. 1998; 279: 1615-1622
Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383–9.
The LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349–57.
- Follow-up study of patients randomized in the Scandinavian Simvastatin Survival Study (4S) of cholesterol lowering.Am. J. Cardiol. 2000; 86: 257-262
- Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.Clin. Chem. 1972; 18: 499-502
Simon Broome Register Group. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Atherosclerosis 1999;142:105–12.
- Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial.Lancet. 2001; 357: 577-581